The Effects of Atypical Antipsychotics on Serum Prolactin Levels

References

• Bole-Feysot C, Goffin V, Edery M, Bin art N, Kelly PA: Pro-lactin (PRL) and its receptor: Actions, signal transduction pathways and phenotypes observed in PRL receptor knock-out mice. Endocr Rev 1998; 19:225–268
   PubMed Web of Science ®Google Scholar
• Muller EE, Locatelli V, Cella S, Penalva A, Novelli A, Cocchi D: Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications. Drugs 1983; 25:399–432
   Google Scholar
• Cowen PJ, Anderson IM, Gartside SE: Endocrinological re-sponses to 5-HT. Ann NY Acad Sci 1990; 600:250–257
   PubMed Web of Science ®Google Scholar
• Fuller RW: Serotonin receptors and neuroendocrine re-sponses. Neuropsychopharmacology 1990; 3:495–502
   PubMed Web of Science ®Google Scholar
• Van de Kar LD, Rittenhouse PA, Li Q, Levy AD: Serotoner-gic regulation of renin and prolactin secretion. Behav Brain Res 1996; 73:203–208
   PubMed Web of Science ®Google Scholar
• Hamner MB, Arana GW: Hyperprolactinaemia in antipsychotic-treated patients: Guidelines for avoidance and management. CNS Drugs 1998; 10:209–222
   Web of Science ®Google Scholar
• Balsa JA, Sanchez-Franco F, Pazos F, Lara JI, Lorenzo MJ, Maldonado G, Cacicedo L: Direct action of serotonin on pro-lactin, growth hormone, corticotropin and luteinizing hor-mone release in cocultures of anterior and posterior pitu-itary lobes: Autocrine and/or paracrine action of vasoactive intestinal peptide. Neuroendocrinology 1998; 68:326–333
   PubMed Web of Science ®Google Scholar
• Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS: 5-HT2A receptors stimulate ACTH, corticosterone, oxy-tocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 2001; 21:3572–3579
   PubMed Web of Science ®Google Scholar
• Dickson RA, Glazer WM: Neuroleptic-induced hyperpro-lactinemia. Schizophr Res 1999; 35(Suppl):S75–86
   Google Scholar
• Brambilla F, Guastalla A, Guerrini A, Rovere C, Legnani G, Sarno M, Riggi F: Prolactin secretion in chronic schizophre-nia. Acta Psychiatr Scand 1976; 54:275–286
   PubMed Web of Science ®Google Scholar
• Kemati D, Maj M, Ariano MG, Arena F, Lever° N: 24-hour plasma levels of prolactin, cortisol, growth hormone and cat-echolamines in schizophrenic patients. Neuropsychobiology 1985; 14:109–114
   Google Scholar
• Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS: A study of serum prolactin levels in schizophrenia: Comparison of males and females. Clin Exp Pharmacol Physiol 1992; 19:603–606
   PubMed Web of Science ®Google Scholar
• Rao ML, Gross G, Halaris A, Huber G, Mader M, Strebei B, Braunig P: Hyperdopaminergia in schizophreniform psychosis: A chronobiological study. Psychiatry Res 1993; 47:187–203
   Google Scholar
• Brown PJ, Cleghorn JM, Brown GM, Kaplan RD, Mitton J. Szechtman H, Szechtman B: Seasonal variations in prolactin levels in schizophrenia. Psychiatry Res 1988; 25:157–162
   Google Scholar
• Kleinman JE, Weinberger DR, Rogol AD, Bigelow LB, Klein ST, Gillin JC, Wyatt RJ: Plasma prolactin concentrations and psychopathology in chronic schizophrenia. Arch Gen Psychi-atry 1982; 39:655–657
   PubMed Web of Science ®Google Scholar
• Naber D, Finkbeiner C, Fischer B, Zander KJ, Ackenheil M: Effect of long-term neuroleptic treatment on prolactin and norepinephrine levels in serum of chronic schizophrenics: Re-lations to psychopathology and extrapyramidal symptoms. Neuropsychobiology 1980; 6:181–189
   Google Scholar
• Luchins DJ, Robertson AG, Meltzer HY: Serum prolactin, psychopathology, and ventricular size in chronic schizophre-nia. Psychiatry Res 1984; 12:149–153
   PubMed Web of Science ®Google Scholar
• Otani K, Kondo T, Ishida M, Tanaka 0, Yasui N, Suzuki A, Kaneko S: Plasma prolactin concentration and psychopathol-ogy of schizophrenia. Prog Neuropsychopharmacol Biol Psy-chiatry 1996; 20:1369–1374
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Fang VS: The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976; 33:279–286
   PubMed Web of Science ®Google Scholar
• Wode-Helgodt B, Eneroth P. Fyro B, Gullberg B, Sedv allG: Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatr Scand 1977; 56:280–293
   Google Scholar
• Cotes PM, Crow TJ, Johnstone EC, Bartlett W, Bourne RC: Neuroendocrine changes in acute schizophrenia as a func-tion of clinical state and neuroleptic medication. Psychol Med 1978; 8:657–665
   Google Scholar
• Gruen PG, Sachar EJ, Altman N, Langer G, Tabrizi MA, Halpern FS: Relation of plasma prolactin to clinical re-sponse in schizophrenic patients. Arch Gen Psychiatry 1978; 35:1222–1227
   PubMed Web of Science ®Google Scholar
• Rao ML, Gross G, Strebel B, Braunig P, Huber G, Klosterkot-ter J: Serum amino acids, central monoamines, and hor-mones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Res 1990; 34:243–257
   Google Scholar
• Spitzer M, Sajjad R, Benjamin F: Pattern of development of hyperprolactinemia after initiation of haloperidol therapy. Obstet Gynecol 1998; 91:693–695
   PubMed Web of Science ®Google Scholar
• Petty RG: Prolactin and antipsychotic medications: Mecha-nism of action. Schizophr Res 1999; 35(Suppl):S67–73
   Google Scholar
• Naber D. Ackenheil M, Laakmann G: Basal and stimu-lated levels of prolactin, TSH, and LH in serum of chronic schizophrenic patients long-term treated with neuroleptics: Relations to psychopathology. Adv Biochem Psychopharma-col 1980; 24:419–423
   Google Scholar
• Kuruvilla A, Srikrishna G, Peedicayil J, Kuruvilla K, Kana-gasabapathy AS: A study on serum prolactin levels in schizophrenia: Correlation with positive and negative symp-toms. lot Clin Psychopharmacol 1993; 8:177–179
   PubMed Web of Science ®Google Scholar
• Brown WA, Laughren TP: Tolerance to the prolactin-elevating effect of neuroleptics. Psychiatry Res 1981; 5:317–322
   PubMed Web of Science ®Google Scholar
• Johnson OF, Hunt GE: The effect of thioridazine on pro-lactin levels in acutely schizophrenic patients: Challenge-dose and steady-state levels. Aust N Z J Psychiatry 1980; 14:127–131
   PubMed Web of Science ®Google Scholar
• Chouinard G, Annable L, Jones BD, Collu R: Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system. Acta Psychiatr Scand 1981; 64:353–362
   PubMed Web of Science ®Google Scholar
• Zelaschi NM, Delucchi GA, Rodriguez JL: High plasma pro-lactin levels after long-term neuroleptic treatment. Biol Psy-chiatry 1996; 39:900–901
   PubMed Web of Science ®Google Scholar
• Kaneda Y, Fujii A: Effects of chronic neuroleptic adminis-tration on the hypothalamo-pituitary-gonadal axis of male schizophrenics. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24:251–258
   PubMed Web of Science ®Google Scholar
• Rao ML, Brown WA: Stability of serum neuroleptic and pro-lactin concentrations during short- and long-term treatment of schizophrenic patients. Psychopharmacology 1987; 93:237–242
   Google Scholar
• Ghadirian AM, Chouinard G, Annable L: Sexual dys-function and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982; 170:463–467
   PubMed Web of Science ®Google Scholar
• Wesselmann U, Windgassen K: Galactorrhea: Subjective re-sponse by schizophrenic patients. Acta Psychiatr Scand 1995; 91:152–155
   Google Scholar
• Aizenberg D, Zemishlany Z, Dorfman-Etrog P, Weizman A: Sexual dysfunction in male schizophrenic patients. J Clin Psy-chiatry 1995; 56:137–141
   Google Scholar
• Arato M, Erdos A, Polgar M: Endocrinological changes in patients with sexual dysfunction under long-term neurolep-tic treatment. Pharmakopsychiatr Neuropsychopharmakol 1979; 12:426–431
   PubMedGoogle Scholar
• Seeman MV, Lang M: The role of estrogens in schizophre-nia gender differences. Schizophr Bull 1990; 16:185–194
   PubMed Web of Science ®Google Scholar
• Riecher-Rossler A, Hafner H, Stumbaum M, Maurer K, Schmidt R: Can estradiol modulate schizophrenic symptoma-tology? Schizophr Bull 1994; 20:203–214
   PubMed Web of Science ®Google Scholar
• Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D: A clinical trial of the effects of estrogen in acutely psy-chotic women. Schizophr Res 1996; 20:247–252
   PubMed Web of Science ®Google Scholar
• Seeman MV: The role of estrogen in schizophrenia. J Psychi-atry Neurosci 1996; 21:123–127
   PubMed Web of Science ®Google Scholar
• Rubinow DR, Schmidt PJ: Androgens, brain, and behavior. Am J Psychiatry 1996; 153:974–984
   PubMed Web of Science ®Google Scholar
• Sternbach H: Age-associated testosterone decline in men: Clinical issues for psychiatry. Am J Psychiatry 1998; 155:1310–1318
   PubMed Web of Science ®Google Scholar
• Ataya K, Mercado A, Kartaginer J, Abbasi A, Moghissi KS: Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril 1988; 50:876–881
   PubMed Web of Science ®Google Scholar
• Abraham G, Friedman RH, Verghese C, de Leon J: Osteo-porosis and schizophrenia: Can we limit known risk factors? Biol Psychiatry 1995; 38:131–132
   Google Scholar
• Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y, Rosan R: Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995; 57:485–491
   PubMed Web of Science ®Google Scholar
• Halbreich U, Palter S: Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes. Schizophr Bull 1996; 22:447–454
   PubMed Web of Science ®Google Scholar
• Katz J, Kunofsky S, Patton RE, Allaway NC: Cancer mortality among patients in New York mental hospitals. Cancer 1967; 20:2194–2199
   Google Scholar
• Overall JE: Prior psychiatric treatment and the development of breast cancer. Arch Gen Psychiatry 1978; 35:898–899
   Google Scholar
• Wagner S, Mantel N: Breast cancer at a psychiatric hospi-tal before and after the introduction of neuroleptic agents. Cancer Res 1978; 38:2703–2708
   Web of Science ®Google Scholar
• Mortensen PB: The occurrence of cancer in first admitted schizophrenic patients. Schizophr Res 1994; 12:185–194
   PubMedGoogle Scholar
• Halbreich U, Shen J, Panaro V: Are chronic psychiatric pa-tients at increased risk for developing breast cancer? [see comments]. Am J Psychiatry 1996; 153:559–560
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Matsubara S, Lee JC: The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25:390–392
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS: Ef-fect of clozapine on human serum prolactin levels. Am J Psy-chiatry 1979; 136:1550–1555
   PubMed Web of Science ®Google Scholar
• Schulz E, Fleischhaker C, Remschmidt HE: Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neu-roleptics in adolescents and young adults with schizophrenia. J Child Adolesc Psychopharmacol 1996; 6:119–131
   PubMed Web of Science ®Google Scholar
• Markianos M, Hatzimanolis J, Lykouras L: Switch from neu-roleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients. Eur Neu-ropsychopharmacol 1999; 9:533–536
   PubMed Web of Science ®Google Scholar
• Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M: Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999; 19:57–61
   PubMed Web of Science ®Google Scholar
• Markianos M, Hatzimanolis J, Lykouras L: Dopamine recep-tor responsivity in schizophrenic patients before and after switch from haloperidol to risperidone. Psychiatry Res 1999; 89:115–122
   PubMed Web of Science ®Google Scholar
• Markianos M, Hatzimanolis J, Lykouras L: Gonadal axis hor-mones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone. Psychopharma-cology (Berl) 1999; 143:270–272
   Google Scholar
• Beasley CM, Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S: Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacol-ogy (Berl) 1996; 124:159–167
   PubMed Web of Science ®Google Scholar
• Beasley CM, Jr., Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111–123
   PubMed Web of Science ®Google Scholar
• Beasley CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin 0, Beuzen JN: Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7:125–137
   PubMed Web of Science ®Google Scholar
• Esel E, Basturk M, Saffet Gonul A, Kula M, Tayfun Turan M, Yabanoglu I, Sofuoglu S: Effects of olanzapine and haloperi-dol on serum prolactin levels in male schizophrenic patients. Psychoneuroendocrinology 2001; 26:641–647
   Google Scholar
• Madhusoodanan S, Brenner R, Suresh P, Concepcion NM, Florita CD, Menon G, Kaur A, Nunez G, Reddy H: Efficacy and tolerability of olanzapine in elderly patients with psy-chotic disorders: A prospective study. Ann Clin Psychiatry 2000; 12:11–18
   PubMedGoogle Scholar
• Ishigooka J, Murasaki M, Miura S: Efficacy and safety of olan-zapine, an atypical antipsychotic, in patients with schizophre-nia: Results of an open-label multicenter study in Japan. Psy-chiatry Clin Neurosci 2001; 55:353–363
   Google Scholar
• Borison RL, Arvanitis LA, Miller BG, US Seroquel Study Group: ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996; 16:158–169
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG: Multiple fixed doses of "Sero-quel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42:233–246
   Google Scholar
• Peuskens J, Link CG: A comparison of quetiapine and chlor-promazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96:265–273
   PubMed Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG, Seroquel Study Group: Quetiapine in patients with schizophrenia. A high- and low-dose double-blind compar-ison with placebo. Arch Gen Psychiatry 1997; 54:549–557
   Google Scholar
• King DJ, Link CG, Kowalcyk B: A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology (Berl) 1998; 137:139–146
   Web of Science ®Google Scholar
• Hamner MB, Arvanitis LA, Miller BG, Link CG, Hong WW: Plasma prolactin in schizophrenia subjects treated with Sero-quel (ICI 204,636). Psychopharmacol Bull 1996; 32:107–110
   PubMed Web of Science ®Google Scholar
• Hamner MB, McConville B: Quetiapine does not produce sustained elevations of prolactin levels. New Research Ab-stracts American Psychiatric Association Annual Meeting Proceedings, 2001; 138
   Google Scholar
• Copolov DL, Link CG, Kowalcyk B: A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med 2000; 30:95–105
   PubMed Web of Science ®Google Scholar
• Emsley RA, Raniwalla J, Bailey PJ, Jones AM: A compar-ison of the effects of quetiapine ('seroquel') and haloperi-dol in schizophrenic patients with a history of and a demon-strated, partial response to conventional antipsychotic treat-ment. PRIZE Study Group. Int Clin Psychopharmacol 2000; 15:121–131
   PubMed Web of Science ®Google Scholar
• Wetzel H, Szegedi A, HaM C, Wiesner J, Schlegel S, Benkert 0: Seroquel (ICI 204 636), a putative "atypical" antipsy-chotic, in schizophrenia with positive symptomatology: Re-sults of an open clinical trial and changes of neuroendocrino-logical and EEG parameters. Psychopharmacology (Berl) 1995; 119:231–238
   PubMed Web of Science ®Google Scholar
• McConville B: Quetiapine does not elevate prolactin in ado-lescents with psychotic disorders, Annual Meeting of the American Psychiatric Association, Chicago, Illinois, May 13–18,2000
   Google Scholar
• Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN: An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998; 18:296–304
   PubMed Web of Science ®Google Scholar
• Miceli JJ, Wilner KD, Hansen RA, Johnson AC, Apseloff G, Gerber N: Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male vol-unteers. Br J Clin Pharmacol 2000; 49:5S–13S
   Google Scholar
• Breier AF, Malhotra AK, Su TP, Finals DA, Elman I, Adler CM, Laf argue RT, Clifton A, Pickar D: Clozapine and risperi-done in chronic schizophrenia: Effects on symptoms, parkin-sonian side effects, and neuroendocrine response. Am J Psy-chiatry 1999; 156:294–298
   PubMed Web of Science ®Google Scholar
• Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Jr., Tollefson GD: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophre-nia and other psychotic disorders [see comments]. J Clin Psy-chopharmacol 1997; 17:407–418
   Google Scholar
• David SR, Taylor CC, Kinon BJ, Breier A: The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000; 22:1085–1096
   PubMed Web of Science ®Google Scholar
• Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P. Bedwell J, Lenane MC, Rapoport JL: Elevated prolactin in pediatric patients on typical and atypical antipsy-chotics. J Child Adolesc Psychopharmacol 1999; 9:239–245
   Google Scholar
• Mullen B, Bran JS, Vagnucci AH, Ganguli R: Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone. Schizophr Res 2001; 48:155–158
   Google Scholar
• Kearns AE, Goff DC, Hayden DL, Daniels GH: Risperidone-associated hyperprolactinemia. Endocr Pract 2000; 6:425–429
   PubMedGoogle Scholar
• Berry SA, Martinez RA, Guldesky GA, Myers 1E, Mahmoud RA: Serum prolactin levels in schizophrenia. New Research Abstracts American Psychiatric Association Annual Meeting Proceedings, 2001:141
   Google Scholar
• Turrone P, Kapur S, Seeman MV, Flint AJ: Elevation of pro-lactin levels by atypical antipsychotics. Am J Psychiatry 2002; 159:133–135
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, Remington G, Houle S: Re-lationship between dopamine D(2) occupancy, clinical re-sponse, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514–520
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky RB, Remington G: Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozap-Me, risperidone, and olanzapine in schizophrenia. Am J Psy-chiatry 1999; 156:286–293
   PubMed Web of Science ®Google Scholar
• Kapur 5, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S: 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. Am J Psy-chiatry 1998; 155:921–928
   PubMed Web of Science ®Google Scholar
• Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B: Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995; 15:19S–23S
   Google Scholar
• Knable MB. Heinz A, Raedler T, Weinberger DR: Extrapyra-midal side effects with risperidone and haloperidol at com-parable D2 receptor occupancy levels. Psychiatry Res 1997; 75:91–101
   PubMed Web of Science ®Google Scholar
• Nyberg S, Farde L, Halldin C: A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997; 16:1–7
   PubMed Web of Science ®Google Scholar
• Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L: Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999; 156:869–875
   PubMed Web of Science ®Google Scholar
• Raedler Ti, Knable MB, Lafargue T, Urbina RA, Egan MF, Pickar D, Weinberger DR: In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine. Psychiatry Res 1999; 90:81–90
   PubMedGoogle Scholar
• Tauscher J, Kufferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C, Tauscher-Wisniewski S, Brucke T, Kasper S: In vivo 1231 IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharma-cology (Berl) 1999; 141:175–181
   PubMed Web of Science ®Google Scholar
• Farde L, Nordstrom AL: PET analysis indicates atypical cen-tral dopamine receptor occupancy in clozapine-treated pa-tients. Br J Psychiatry Suppl 1992:30–33
   Google Scholar
• Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to ex-trapyramidal side effects. Arch Gen Psychiatry 1992; 49:538–544
   PubMed Web of Science ®Google Scholar
• Gefvert 0, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R: Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Sero-quel) in patients with schizophrenia. Psychopharmacology (Berl) 1998; 135:119–126
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P: A positron emission tomography study of queti-apine in schizophrenia: A preliminary finding of an antipsy-chotic effect with only transiently high dopamine 02 receptor occupancy. Arch Gen Psychiatry 2000; 57:553–559
   PubMed Web of Science ®Google Scholar
• Stephenson CM, Bigliani V, Jones HM, Kerwin RW, Pilowsk y LS, Mulligan RS, Visvikis D, Ell PJ, Acton PD: Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo: [(123)I1-epidepride single photon emission tomography (SPET) study. Br J Psychiatry 2000; 177:408–415
   PubMedGoogle Scholar
• Kapur S, Seeman P: Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001; 158:360–369
   PubMed Web of Science ®Google Scholar